tepotinib

Drug Code : 2202162943

Drug Brand : Tepmetko

Company : EMD Serono

Approved by : FDA, MHLW, NCCN

Approval Time : Feb. 3, 2021

Direct Target : MET

Drug Type : Single-target inhibitor

Gene : MET

Alteration : Positive Expression

Disease : Non-Small Cell Lung Cancer

Indications : Tepotinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Mechanism Of Action :

Clinical Trial : NCT02864992

Dosage : The recommended tepotinib dose is 450 mg orally once daily with food.

Reference Source :

Structure :

 Related Targets and Diseases

Drug Name	Gene		Disease		Negative Genotypes	Drug Brand		Drug Type

Reference List :